Maschan Alexey, Novichkova Galina, Miakova Natalia, Persiantseva Marina
Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation, Moscow, Russia.
Pediatr Blood Cancer. 2016 Dec;63(12):2243-2245. doi: 10.1002/pbc.26148. Epub 2016 Jul 19.
An 11-year-old male was diagnosed with chronic-phase chronic myeloid leukemia (CML) in 1998 and received therapy with interferon-α2b and low-dose cytarabine. In 6 years, he progressed to lymphoid blast crisis and received induction chemotherapy with prednisolone, vincristine, daunorubicin, and l-asparaginase concomitantly with imatinib 400 mg/day, and continuation with vincristine + prednisolone, cytarabine + etoposide, vincristine + l-asparaginase, cyclophosphamide + etoposide, and 6-mercaptopurine + methotrexate. Complete molecular response (MR) was achieved and therapy was continued with imatinib 800 mg/day. He relapsed to chronic-phase CML after interruption of imatinib and regained MR after its restart. The patient is alive 17.5 years after CML diagnosis and 11.5 years after lymphoid blast crisis.
一名11岁男性于1998年被诊断为慢性期慢性髓性白血病（CML），并接受了α-干扰素2b和小剂量阿糖胞苷治疗。6年后，他进展为淋巴细胞母细胞危象，接受了泼尼松龙、长春新碱、柔红霉素和L-天冬酰胺酶诱导化疗，同时服用伊马替尼400毫克/天，后续继续使用长春新碱+泼尼松龙、阿糖胞苷+依托泊苷、长春新碱+L-天冬酰胺酶、环磷酰胺+依托泊苷以及6-巯基嘌呤+甲氨蝶呤治疗。实现了完全分子学缓解（MR），并继续使用伊马替尼800毫克/天治疗。伊马替尼中断后，他复发为慢性期CML，重新使用伊马替尼后再次获得MR。该患者在CML诊断后17.5年以及淋巴细胞母细胞危象后11.5年仍然存活。
